India stuck to TRIPS and domestic law in UK deal, says official amid drug access concerns
The 'Working Group on Access to Medicines and Treatment' and trade experts pointed out that the UK deal has provisions tilting in favour of patent holders since they bring the issuance of compulsory licences — a critical tool to ensure access to affordable life-saving medicines — under greater scrutiny and constraints.
'In the IPR chapter, India has not breached the TRIPS agreement and is in compliance with domestic law. Only best practices that do not infringe on domestic laws have been adopted. Sharing of information and several such elements are part of the deal,' the government official said.
The Working Group on Access to Medicines and Treatment is a network of patients, activists and professionals working towards access to affordable medicines in India. It said the UK-India FTA provisions on patents tilt the balance in favour of the patent owner and undermine access to medicines.
'There is a progressive movement towards accepting the demands of FTA partners, which is systematically debasing the public interest safeguards available in the Indian Patents Act. Article 13.6, stating the understandings regarding TRIPS and public health measures, clearly places voluntary mechanisms such as voluntary licensing as the preferred and optimal route to promote access to medicines,' the working group said.
Biswajit Dhar, a trade policy expert with the Council for Social Development, said that the provisions in the UK deal favouring voluntary licences leave access to medicines in the hands of market forces and undermine the role of the government in facilitating access.
'Further, it also gives a clear signal to potential compulsory licence applicants that they are not welcome. Often, voluntary licences contain onerous conditions on the licensee and fail to bring sharp price reductions compared to compulsory licences,' Dhar said.
'There are also provisions in the IP chapter which can potentially undermine the safeguards preventing evergreening of patents. Though couched in best endeavour language, there is a provision to 'facilitate the sharing and use of search and examination work of the Parties'. The implementation of this provision would lead to the harmonisation of patentability criteria and undermine safeguards against evergreening, such as Section 3(d) of the Patents Act,' said K M Gopakumar, co-convenor of the Working Group on Access to Medicines and Treatment.
Compared to the European Free Trade Association (EFTA) IP chapter, this chapter shows further movement towards strengthening the interests of patent holders at the cost of access to medicines. The implementation of these provisions reduces the ability of the central and state governments to fulfil their constitutional obligation on the right to health, the working group said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
6 hours ago
- Time of India
Safeguards for generics in UK FTA: Govt
New Delhi: The India-UK free trade agreement (FTA) does not mandate patent term extensions or data exclusivity, which are two common tools of evergreening of patents, the commerce and industry ministry said Monday, adding that this would protect the interests of the domestic generic drugs industry . Data exclusivity provides protection to the technical data generated by innovator companies to prove the usefulness of their products. "The FTA does not mandate patent term extensions or data exclusivity-two common tools of evergreening. India's patent law provisions on patentability criteria under Section 3(d) (of Indian Patent Act) remain fully protected," the ministry said. It prohibits the grant of 'evergreening' patents, which are additional patents for a drug with no therapeutic benefit and are seen to increase the term of a patent monopoly. Explore courses from Top Institutes in Please select course: Select a Course Category Cybersecurity Technology Digital Marketing MCA Finance Operations Management Project Management Public Policy Management Artificial Intelligence CXO Data Science Healthcare Data Science Others healthcare others MBA Data Analytics Degree Leadership Design Thinking Product Management PGDM Skills you'll gain: Duration: 10 Months MIT xPRO CERT-MIT xPRO PGC in Cybersecurity Starts on undefined Get Details The UK was demanding for inclusion of "data exclusivity" provision in the agreement. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Why Your Current Make-Up Routine Might Be Aging You Learn More Undo India had earlier rejected a similar demand on data exclusivity from the four-nation EFTA bloc in their free trade agreement negotiations. The India-UK comprehensive economic and trade agreement (CETA) was signed on July 24. India's generic drug industry is estimated to be about $25 billion and it exports 50% of its produce. Live Events "The FTA does not require India to provide patent term extensions for regulatory delays and data exclusivity for pharmaceuticals or agrochemicals," it said, adding that this ensures that generic manufacturers can enter the market without unnecessary delay, once the patent has expired or is challenged. CETA, it said, does not alter India's ability to refuse patents for minor modifications of known substances; and prevent frivolous or repetitive patent filings blocking generics. Farm access The ministry also said India is giving duty concessions to niche British agricultural products like cranberries, durians, certain varieties of mushrooms, leeks, lettuce, and artichokes under the trade pact. These products have negligible production in India,it said. However, India is not giving any concession on sensitive items like apples, pineapples, oranges, and pomegranates in the CETA. Over 95% of Indian tariff lines or product categories in the agri sector will now enjoy zero-duty access to the UK market. "India-UK CETA will allow Indian farmers to fetch premium prices for their products in the UK market, thereby granting parity with major EU exporters like Germany and Netherlands, who currently enjoy zero tariffs," it said. It said major gains are estimated for fresh grapes; bakery items, onions and mixed vegetables. Services Companies from the UK will be able to offer services in telecom and construction in India without setting up a local presence and British firms will be treated on par with Indian firms.
&w=3840&q=100)
Business Standard
8 hours ago
- Business Standard
Peru pitches critical minerals to Indian firms, FTA likely by early 2026
Amid concerns over China's ban on the export of rare earths, Peru has invited Indian companies to invest, start joint venture exploration, and establish technological tie-ups in the sector to source these critical minerals from the Latin American nation. A top diplomat from the Latin American country said on Monday in Chennai that both India and Peru are expected to finalise a comprehensive Free Trade Agreement (FTA) by the end of this year or early 2026. 'Of special relevance to today's world—and to India's strategic ambitions in clean energy and advanced technologies—are Peru's deposits of rare earth minerals, including neodymium, praseodymium, dysprosium, and terbium. Peru welcomes Indian investment, joint exploration initiatives, and technological collaboration in this vital sector,' said Javier Manuel Paulinich Velarde, Ambassador of Peru to India. Addressing the first official Peruvian National Day celebration in Chennai, he added that these critical minerals are essential for the production of electric vehicles, wind turbines, electronics, and next-generation defence systems. 'By the end of this year or early 2026, we expect to conclude the Free Trade Agreement negotiations, unlocking mutual opportunities in trade, investment, agribusiness, pharmaceuticals, and technology,' Velarde said. India is now Peru's third-largest trading partner in the Latin American and Caribbean region. The India–Peru economic partnership has seen significant momentum in recent years, with bilateral trade growing from $2.34 billion in 2019–20 to $4.03 billion in 2023–24. 'As Peru emerges as a key source of critical minerals including rare-earth magnets, copper, and lithium, we see great potential for Tamil Nadu-based manufacturing industries to forge mutually beneficial partnerships,' said R. Dinesh, Honorary Consul of Peru in Chennai and Chairman of TVS Supply Chain Solutions. 'I strongly believe that the deep, shared interests between India and Peru can foster meaningful collaborations among entrepreneurs, investors, and institutions—driving outcomes that are both commercially rewarding and culturally enriching,' Dinesh said. Velarde also invited Indian companies to explore investment opportunities in the port and logistics sector. 'Peru's strategic location on the South Pacific, supported by a modern and expanding maritime infrastructure, positions us as a logistics hub and gateway to Asia—including India. This translates into lower shipping costs, shorter delivery times, and greater opportunities for regional integration. We are also pleased to highlight that new investment opportunities remain open in our port and logistics sectors,' he added. The ongoing negotiations for a comprehensive Free Trade Agreement (FTA) between the two countries are expected to deepen market access and address both tariff and non-tariff barriers. Once finalised, the FTA is expected to open up new opportunities in goods, services, and investments, particularly in sectors such as healthcare, renewable energy, digital technology, and clean mobility. 'Tamil Nadu is uniquely positioned to engage with Peru—a country rich in resources, business potential, and culture. Key sectors such as mining, automobiles, IT, agriculture, and horticulture present significant opportunities for collaboration,' he added.
Economic Times
12 hours ago
- Economic Times
India, UK trade pact does not mandate patent term extensions or data exclusivity
Representative image The India-UK free trade agreement (FTA) does not mandate patent term extensions or data exclusivity, which are two common tools of evergreening of patents, according to a commerce ministry document. The move would protect the interests of the domestic generic drugs industry. The UK was demanding for inclusion of "data exclusivity" provision in the agreement. "The FTA does not mandate patent term extensions or data exclusivity -- two common tools of evergreening. India's patent law provisions on patentability criteria under Section 3(d) (of Indian Patent Act) remain fully protected," the ministry said. Section 3(d) of the Indian Patents Act, 1970, restricts patents for already-known drugs unless the new claims are superior in terms of efficacy, while Section 3(b) bars patents for products that are against public interest and do not demonstrate enhanced efficacy over existing products. Certain multinational firms have asked India to amend these laws, which were strongly opposed. The agreement, signed on July 24, may take about a year to come into force. Data exclusivity provides protection to the technical data generated by innovator companies to prove the usefulness of their products. In the pharmaceutical sector, drug companies generate data through expensive global clinical trials to prove the efficacy and safety of their new medicine. By gaining exclusive rights over this data, innovator companies can prevent their competitors from obtaining a marketing licence for low-cost versions during the tenure of this exclusivity. Earlier, India had also rejected a similar demand from the four-nation EFTA bloc in their free trade agreement negotiations. The European Free Trade Association (EFTA) members are Iceland, Liechtenstein, Norway, and Switzerland. The pact was signed in March 2023 and will be implemented later this year. The UK (AstraZeneca and GSK) and Switzerland (Novartis and Roche) have some of the major pharma firms of the world. India's generic drug industry is estimated about USD 25 billion, and the country exports 50 per cent of its produce. An expert said data exclusivity is beyond the provisions of the Trade Related Aspects of Intellectual Property Rights (TRIPS) agreement under the World Trade Organization (WTO). Evergreening of patent rights is a strategy allegedly adopted by the innovators having patent rights over products to renew them by bringing in some minor changes, such as adding new mixtures or formulations. It is done when their patent is about to expire. A patent on the new form gives the innovator company a 20-year monopoly on the drug. "The FTA does not require India to provide patent term extensions for regulatory delays and data exclusivity for pharmaceuticals or agrochemicals," it said, adding that this ensures that generic manufacturers can enter the market without unnecessary delay, once the patent has expired or is challenged. The agreement, it said, does not alter or dilute India's ability to refuse patents for minor modifications of known substances; and prevent frivolous or repetitive patent filings that block generics. "There is no obligation for patent linkage or automatic injunctions either-key tools used to delay generics in other jurisdictions," the ministry said.
